Radioprotective effect of p53 against oral mucositis
p53对口腔粘膜炎的放射防护作用
基本信息
- 批准号:10775974
- 负责人:
- 金额:$ 50.68万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-09-07 至 2028-06-30
- 项目状态:未结题
- 来源:
- 关键词:AccelerationAcuteAffectAllelesBlood capillariesBody WeightBody Weight decreasedC57BL/6 MouseCell Cycle ArrestCell DeathCell LineageCell ProliferationCell SurvivalCellsDNA DamageDNA MarkersDataDefectDilatation - actionDose LimitingEpithelial CellsEpitheliumExhibitsG2/M Checkpoint PathwayGADD45A geneGenetic TranscriptionGenetically Engineered MouseGoalsHead and Neck Squamous Cell CarcinomaHead and neck structureHistopathologyHumanHuman PapillomavirusImpairmentIncidenceInflammationInjuryIntakeKnockout MiceMaintenanceMalignant NeoplasmsMediatingMetabolicMitosisMitoticModelingMusMutateMutationMyeloid CellsNatural regenerationNormal tissue morphologyNutritional statusOralOral mucous membrane structurePatient-Focused OutcomesPatientsPersonsPlayRadiationRadiation InjuriesRadiation ProtectionRadiation therapyRecoveryRoleSignal TransductionSomatic CellStressSuperoxide DismutaseTP53 geneTestingTherapeuticToxic effectTransactivationTransplantationUnited StatesVascular Endothelial Cellclinical developmentexperimental studygain of functiongenome integrityin vivoinhibitorinsightirradiationknock-downloss of functionmimeticsmouse modelmutantnovelnovel therapeutic interventionopioid useoral cavity epitheliumoral mucositispharmacologicpreventradiation responseresponsesmall hairpin RNAsmall moleculetreatment responsetumor
项目摘要
ABSTRACT
Head and neck squamous cell carcinoma (HNSCC) represents the sixth most common cancer
worldwide. The Global Cancer Observatory predicts a 30% increase in annual incidence by 2030 with
approximately 1.08 million new cases/year. Radiation therapy (RT) plays an integral role in treating HNSCC;
however, head and neck RT is associated with significant toxicity in the oral mucosa. This toxicity, termed
radiation-induced oral mucositis (RIOM), can lead to opioid use, reduced oral intake/poor nutritional status, and
the need for treatment breaks, all of which are correlated with worse outcomes for patients with HNSCC. As
current treatment options for RIOM are limited, there is an unmet need to develop novel radioprotectors that
will widen the therapeutic window of head and neck RT. Our long-term goal aims to develop novel therapeutic
strategies that will prevent or reduce RIOM without sacrificing tumor control. The overall objective of this
application is to define the role of p53 in regulating RIOM. The p53 gene is mutated in >80% of human
papillomavirus negative HNSCC, yet it remains wild type in adjacent normal tissues. The p53 protein plays a
critical role in regulating various cellular responses to stress such as cell death, cell survival, metabolic
adaptation, and maintenance of genomic integrity. In normal oral epithelium, RT markedly increases the level
of p53 protein as well as its transcriptional target and negative regulator Mdm2. However, how p53 affects
damage and recovery of the oral epithelium following irradiation remains poorly understood. Based on our
preliminary data generated from p53 knockout mice, we hypothesize that the response of p53 to acute DNA
damage plays a crucial role in promoting the regeneration of oral epithelium following severe radiation injury.
Therefore, treatment with Mdm2 inhibitors that enhance p53-dependent signaling specifically in cells harboring
a functional p53 protein before and during RT will ameliorate acute injury of p53 wild-type oral epithelium
without decreasing the therapeutic response of p53 mutant HNSCC. We will test this hypothesis through both
loss-of-function and gain-of-function approaches to modulate the response of p53 to radiation using genetically
engineered mouse models and small molecule Mdm2 inhibitors. The impact of Mdm2 inhibition on RIOM will
be evaluated in normal and tumor-bearing mice. Successful completion of the proposed study will provide
mechanistic insights into the crucial role of p53 in promoting the regeneration of oral epithelium following acute
radiation injury. Our findings will provide a proof-of-concept to support clinical development of Mdm2 inhibitors
as radioprotectors for RIOM to widen the therapeutic window of RT for treating p53 mutant HNSCC.
摘要
头颈部鳞状细胞癌(HNSCC)是第六常见的癌症
国际吧全球癌症观察站预测,到2030年,
每年新增病例约108万例。放射治疗(RT)在治疗HNSCC中起着不可或缺的作用;
然而,头部和颈部RT与口腔粘膜中的显著毒性相关。这种毒性被称为
辐射诱发的口腔粘膜炎(RIOM),可导致阿片类药物使用、口服摄入量减少/营养状况差,
需要中断治疗,所有这些都与HNSCC患者的不良结局相关。作为
目前RIOM的治疗选择是有限的,开发新的辐射防护剂的需求未得到满足,
我们的长期目标是开发新的治疗方法,
在不牺牲肿瘤控制的情况下预防或减少RIOM的策略。本报告的总体目标
应用的目的是确定p53在调节RIOM中的作用。p53基因在80%以上的人中是突变的。
HNSCC是乳头瘤病毒阴性的HNSCC,但其在邻近正常组织中保持野生型。p53蛋白在肿瘤中起着重要作用。
在调节对应激的各种细胞反应如细胞死亡、细胞存活、代谢和免疫应答中起关键作用。
适应和维持基因组的完整性。在正常口腔上皮中,RT显著增加
p53蛋白及其转录靶点和负调控因子Mdm 2。p53如何影响
辐照后口腔上皮的损伤和恢复仍然知之甚少。基于我们
从p53基因敲除小鼠产生的初步数据,我们假设p53对急性DNA损伤的反应,
损伤在促进严重辐射损伤后口腔上皮的再生中起关键作用。
因此,用Mdm 2抑制剂治疗可以特异性地增强携带p53的细胞中的p53依赖性信号传导,
RT前和RT期间的功能性p53蛋白将改善p53野生型口腔上皮的急性损伤
而不降低p53突变型HNSCC的治疗反应。我们将通过以下两个方面来检验这一假设:
利用基因工程技术调节p53对辐射反应的功能丧失和功能获得方法
工程小鼠模型和小分子Mdm 2抑制剂。Mdm 2抑制对RIOM的影响将
在正常和荷瘤小鼠中进行评估。成功完成拟议的研究将提供
p53在促进口腔上皮细胞急性损伤后再生中的关键作用的机制研究
辐射损伤我们的研究结果将为Mdm 2抑制剂的临床开发提供概念验证
作为RIOM的辐射保护剂,以拓宽RT治疗p53突变型HNSCC的治疗窗。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Chang-Lung Lee其他文献
Chang-Lung Lee的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Chang-Lung Lee', 18)}}的其他基金
Inhibition of CaMKK2 sensitizes rectal cancers to radiation therapy
CaMKK2 的抑制使直肠癌对放射治疗敏感
- 批准号:
10312803 - 财政年份:2021
- 资助金额:
$ 50.68万 - 项目类别:
Inhibition of CaMKK2 sensitizes rectal cancers to radiation therapy
CaMKK2 的抑制使直肠癌对放射治疗敏感
- 批准号:
10112586 - 财政年份:2021
- 资助金额:
$ 50.68万 - 项目类别:
Minimizing the risk of therapy-related myeloid neoplasms by inhibiting genotoxic stress-induced expansion of leukemia-initiating cells with p53 mutations
通过抑制基因毒性应激诱导的 p53 突变白血病起始细胞的扩增,最大限度地降低治疗相关的骨髓肿瘤的风险
- 批准号:
10113420 - 财政年份:2020
- 资助金额:
$ 50.68万 - 项目类别:
Minimizing the risk of therapy-related myeloid neoplasms by inhibiting genotoxic stress-induced expansion of leukemia-initiating cells with p53 mutations
通过抑制基因毒性应激诱导的 p53 突变白血病起始细胞的扩增,最大限度地降低治疗相关的骨髓肿瘤的风险
- 批准号:
10310505 - 财政年份:2020
- 资助金额:
$ 50.68万 - 项目类别:
Dissecting mechanism(s) by which ionizing radiation promotes clonal expansion of premalignant cells in the thymus
剖析电离辐射促进胸腺癌前细胞克隆扩张的机制
- 批准号:
9353350 - 财政年份:2016
- 资助金额:
$ 50.68万 - 项目类别:
相似海外基金
Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
- 批准号:
MR/Y009568/1 - 财政年份:2024
- 资助金额:
$ 50.68万 - 项目类别:
Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
- 批准号:
10090332 - 财政年份:2024
- 资助金额:
$ 50.68万 - 项目类别:
Collaborative R&D
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
- 批准号:
MR/X02329X/1 - 财政年份:2024
- 资助金额:
$ 50.68万 - 项目类别:
Fellowship
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
- 批准号:
MR/X021882/1 - 财政年份:2024
- 资助金额:
$ 50.68万 - 项目类别:
Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
- 批准号:
2312694 - 财政年份:2024
- 资助金额:
$ 50.68万 - 项目类别:
Standard Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
- 批准号:
EP/Y003527/1 - 财政年份:2024
- 资助金额:
$ 50.68万 - 项目类别:
Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
- 批准号:
EP/Y030338/1 - 财政年份:2024
- 资助金额:
$ 50.68万 - 项目类别:
Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
- 批准号:
MR/X029557/1 - 财政年份:2024
- 资助金额:
$ 50.68万 - 项目类别:
Research Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
- 批准号:
24K19395 - 财政年份:2024
- 资助金额:
$ 50.68万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Acute human gingivitis systems biology
人类急性牙龈炎系统生物学
- 批准号:
484000 - 财政年份:2023
- 资助金额:
$ 50.68万 - 项目类别:
Operating Grants